Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...